MX2019008196A - Microorganismos programados para producir moduladores inmunes y productos terapéuticos anti-cáncer en células tumorales. - Google Patents
Microorganismos programados para producir moduladores inmunes y productos terapéuticos anti-cáncer en células tumorales.Info
- Publication number
- MX2019008196A MX2019008196A MX2019008196A MX2019008196A MX2019008196A MX 2019008196 A MX2019008196 A MX 2019008196A MX 2019008196 A MX2019008196 A MX 2019008196A MX 2019008196 A MX2019008196 A MX 2019008196A MX 2019008196 A MX2019008196 A MX 2019008196A
- Authority
- MX
- Mexico
- Prior art keywords
- microorganisms
- programmed
- tumor cells
- cancer therapeutics
- immune modulators
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5443—IL-15
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/57—IFN-gamma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2405—Glucanases
- C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2474—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01035—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y307/00—Hydrolases acting on carbon-carbon bonds (3.7)
- C12Y307/01—Hydrolases acting on carbon-carbon bonds (3.7) in ketonic substances (3.7.1)
- C12Y307/01003—Kynureninase (3.7.1.3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/002—Vectors comprising a special translation-regulating system controllable or inducible
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01003—Glucan 1,4-alpha-glucosidase (3.2.1.3), i.e. glucoamylase
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Se describen microorganismos programados genéticamente, tales como bacterias o virus, composiciones farmacéuticas de los mismos, y métodos de modulación y tratamiento de cánceres.
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762443634P | 2017-01-06 | 2017-01-06 | |
US201762443639P | 2017-01-06 | 2017-01-06 | |
PCT/US2017/013072 WO2017123675A1 (en) | 2016-01-11 | 2017-01-11 | Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells |
US201762531784P | 2017-07-12 | 2017-07-12 | |
US201762543322P | 2017-08-09 | 2017-08-09 | |
US201762552319P | 2017-08-30 | 2017-08-30 | |
US201762592317P | 2017-11-29 | 2017-11-29 | |
US201762607210P | 2017-12-18 | 2017-12-18 | |
PCT/US2018/012698 WO2018129404A1 (en) | 2017-01-06 | 2018-01-05 | Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019008196A true MX2019008196A (es) | 2019-12-16 |
Family
ID=62790899
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019008196A MX2019008196A (es) | 2017-01-06 | 2018-01-05 | Microorganismos programados para producir moduladores inmunes y productos terapéuticos anti-cáncer en células tumorales. |
Country Status (11)
Country | Link |
---|---|
US (2) | US11471494B2 (es) |
EP (1) | EP3565566A1 (es) |
JP (1) | JP2020505016A (es) |
CN (1) | CN110913875A (es) |
AU (1) | AU2018205276A1 (es) |
BR (1) | BR112019013863A2 (es) |
CA (1) | CA3049579A1 (es) |
IL (1) | IL267830A (es) |
MX (1) | MX2019008196A (es) |
SG (1) | SG11201906161VA (es) |
WO (1) | WO2018129404A1 (es) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017123675A1 (en) | 2016-01-11 | 2017-07-20 | Synlogic, Inc. | Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells |
EP3565566A1 (en) * | 2017-01-06 | 2019-11-13 | Synlogic Operating Company, Inc. | Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells |
JP7097438B2 (ja) | 2017-07-11 | 2022-07-07 | アクティム・セラピューティクス・インコーポレイテッド | 遺伝子操作された免疫刺激性細菌菌株およびその使用 |
KR20200064980A (ko) * | 2017-07-12 | 2020-06-08 | 신로직 오퍼레이팅 컴퍼니, 인코포레이티드 | 종양 세포에서 면역 조절제 및 항-암 치료제를 생산하도록 프로그램된 미생물 |
BR112021000315A2 (pt) | 2018-07-11 | 2021-08-03 | Actym Therapeutics, Inc. | cepas bacterianas imunoestimulantes modificadas geneticamente e seus usos |
WO2020018989A1 (en) * | 2018-07-20 | 2020-01-23 | The Trustees Of Columbia University In The City Of New York | Programmable bacteria for the treatment of cancer |
CN112513276B (zh) * | 2018-07-30 | 2024-03-15 | 张晋宇 | 蛋白质异二聚体及其用途 |
EP3844276A2 (en) | 2018-08-28 | 2021-07-07 | Actym Therapeutics, Inc. | Engineered immunostimulatory bacterial strains and uses thereof |
US20220023358A1 (en) * | 2018-11-08 | 2022-01-27 | Synlogic Operating Company, Inc. | Combination therapies of microorganisms and immune modulators for use in treating cancer |
CN109750054B (zh) * | 2019-02-21 | 2021-07-02 | 华中农业大学 | 一种牛支原体蛋白基因MbovGdpP及其应用 |
CA3131017A1 (en) | 2019-02-27 | 2020-09-03 | Actym Therapeutics, Inc. | Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment |
CN110055188A (zh) * | 2019-03-07 | 2019-07-26 | 南京师范大学 | 一株产抑菌肽的多粘类芽孢杆菌xw4及其分离筛选和应用 |
KR20220003030A (ko) | 2019-04-29 | 2022-01-07 | 신로직 오퍼레이팅 컴퍼니, 인코포레이티드 | 살아 있는 세포 계수 기술에 의한 유전적으로 조작된 미생물의 계수 |
EP3969601A4 (en) * | 2019-05-13 | 2022-12-28 | Synlogic Operating Company, Inc. | SYNERGIC COMBINATIONS OF ARGININE-PRODUCING BACTERIA AND/OR AMMONIA-consuming BACTERIA AND CHECKPOINT INHIBITORS AND METHODS OF USE THEREOF |
CN110734888B (zh) * | 2019-09-17 | 2021-08-03 | 广州维生君生物科技有限公司 | Tim3人源单链抗体融合基因转化乳酸菌及其应用 |
CA3161450A1 (en) | 2019-11-12 | 2021-05-20 | Actym Therapeutics, Inc. | Immunostimulatory bacteria delivery platforms and their use for delivery of therapeutic products |
CN111254087B (zh) * | 2019-12-27 | 2021-12-17 | 杭州娃哈哈科技有限公司 | 一株具有增强免疫力功能的高黏附性能瑞士乳杆菌及其应用 |
CA3167223A1 (en) * | 2020-02-13 | 2021-08-19 | William R. Bishai | Recombinant therapeutic interventions for cancer |
WO2021163490A1 (en) * | 2020-02-14 | 2021-08-19 | University Of Washington | Targeted depletion of bacteria from mixed populations through programmable cell-cell adhesion |
EP4135733A2 (en) * | 2020-04-17 | 2023-02-22 | University of Cincinnati | Engineered probiotics for treatment and immunity against viruses |
WO2021252519A1 (en) * | 2020-06-08 | 2021-12-16 | University Of Florida Research Foundation, Inc. | Materials and methods for the diagnosis and treatment of cancer |
CN111849805B (zh) * | 2020-06-17 | 2022-04-22 | 天津科技大学 | 一种具有抗***作用的乳酸片球菌及应用 |
CN116113425A (zh) * | 2020-07-07 | 2023-05-12 | 丹麦科技大学 | 用于工程化非吞噬性免疫细胞的细菌载体 |
AU2021324883A1 (en) | 2020-08-12 | 2023-03-23 | Actym Therapeutics, Inc. | Immunostimulatory bacteria-based vaccines, therapeutics, and rna delivery platforms |
CN114073777A (zh) * | 2020-08-18 | 2022-02-22 | 中国科学院深圳先进技术研究院 | 携带细胞因子或其多核苷酸的细菌靶向载体及其在肿瘤治疗中的应用 |
EP4232069A1 (en) * | 2020-10-26 | 2023-08-30 | Cytune Pharma | Il-2/il-15rbetagamma agonist for treating squamous cell carcinoma |
EP4232068A1 (en) * | 2020-10-26 | 2023-08-30 | Cytune Pharma | IL-2/IL-15RBetaGamma AGONIST FOR TREATING NON-MELANOMA SKIN CANCER |
CN112342233B (zh) * | 2020-11-10 | 2022-08-26 | 上海陶宇晟生物技术有限责任公司 | 用于细菌表达DacA时提高c-di-AMP产量的多核苷酸 |
CA3200887A1 (en) | 2020-12-02 | 2022-06-09 | Michael James | Engineered microorganisms |
KR102287114B1 (ko) * | 2021-01-25 | 2021-08-06 | 씨제이제일제당 주식회사 | 신규한 사이토신 퍼미에이즈 변이체 및 이를 이용한 l-트립토판 생산 방법 |
CN112877271B (zh) * | 2021-02-05 | 2023-03-14 | 江西师范大学 | 一种提高钝齿棒杆菌厌氧发酵产l-精氨酸的方法 |
WO2022221273A1 (en) * | 2021-04-13 | 2022-10-20 | Synlogic Operating Company, Inc. | Bacteria engineered to secrete active proteins |
US20240139280A1 (en) * | 2021-04-14 | 2024-05-02 | OncoC4, Inc. | Use of hif-1-alpha inhibitors in cancer immunotherapy |
CA3235418A1 (en) | 2021-11-09 | 2023-05-19 | Actym Therapeutics, Inc. | Immunostimulatory bacteria for converting macrophages into a phenotype amenable to treatment, and companion diagnostic for identifying subjects for treatment |
CN114181863B (zh) * | 2021-12-15 | 2023-06-23 | 安徽师范大学 | 一种紫色杆菌属菌株e1及其制备方法和在降解邻苯二甲酸酯上的应用 |
WO2023161371A1 (en) * | 2022-02-25 | 2023-08-31 | Danmarks Tekniske Universitet | Engineered bacteria secreting cytokines for use in cancer immunotherapy |
CN116836283B (zh) * | 2022-05-17 | 2024-05-07 | 苏州万灏生物科技有限公司 | 具有多种免疫调节因子的增强型溶瘤病毒及其制备方法和应用 |
CN114958891B (zh) * | 2022-05-24 | 2023-04-14 | 郑州大学 | 一种大肠杆菌重组表达载体及其应用 |
WO2024075067A1 (en) * | 2022-10-06 | 2024-04-11 | Centro Di Riferimento Oncologico | Cancer vaccine composition that comprises a host cell expressing glypican-1 (gpc-1) |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
GB9107305D0 (en) | 1991-04-08 | 1991-05-22 | Unilever Plc | Probiotic |
US6203797B1 (en) | 1998-01-06 | 2001-03-20 | Stephen C. Perry | Dietary supplement and method for use as a probiotic, for alleviating the symptons associated with irritable bowel syndrome |
EP1034787A1 (en) | 1999-03-11 | 2000-09-13 | Société des Produits Nestlé S.A. | Lactobacillus strains preventing diarrhea caused by pathogenic bacteria |
US6962696B1 (en) * | 1999-10-04 | 2005-11-08 | Vion Pharmaceuticals Inc. | Compositions and methods for tumor-targeted delivery of effector molecules |
AU783714B2 (en) * | 1999-10-04 | 2005-12-01 | Vion Pharmaceuticals, Inc. | Compositions and methods for tumor-targeted delivery of effector molecules |
ES2528384T3 (es) | 2001-12-12 | 2015-02-09 | The Government Of The United States Of America, As Represented By The Secretary Department Of Healt | Métodos de utilización de inhibidores del receptor de adenosina para potenciar la respuesta inmunitaria y la inflamación |
US7731976B2 (en) | 2003-08-29 | 2010-06-08 | Cobb And Company, Llp | Treatment of irritable bowel syndrome using probiotic composition |
AU2007241023B2 (en) | 2006-03-30 | 2013-11-28 | University Of California | Methods and compositions for localized secretion of anti-CTLA-4 antibodies |
TW200819540A (en) | 2006-07-11 | 2008-05-01 | Genelux Corp | Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders |
US20080057034A1 (en) | 2006-07-19 | 2008-03-06 | North Carolina State University | Attenuated FNR Deficient Enterobacteria |
US9061048B2 (en) * | 2010-12-15 | 2015-06-23 | The Regents Of The University Of California | Cyclic di-AMP induction of type I interferon |
US9409950B2 (en) | 2010-12-23 | 2016-08-09 | Biogen Ma Inc. | Linker peptides and polypeptides comprising same |
CN102604949A (zh) | 2011-04-12 | 2012-07-25 | 南京大学 | 一种乙醇脱氢酶启动子驱动的厌氧组织选择性基因表达方法及应用 |
HUE050875T2 (hu) | 2012-01-17 | 2021-01-28 | Univ Leland Stanford Junior | Nagy affinitású SIRP-alfa reagensek |
US9127284B2 (en) | 2012-05-04 | 2015-09-08 | The University Of Hong Kong | Modified bacteria and their uses thereof for the treatment of cancer or tumor |
CA2884816A1 (en) | 2012-09-13 | 2014-03-20 | Massachusetts Institute Of Technology | Programmable drug delivery profiles of tumor-targeted bacteria |
EP2916854A4 (en) * | 2012-11-06 | 2016-06-22 | Aduro Biotech Inc | BACTERIAL SPECIES WHICH CAN BE MISSED AND METHODS OF PREPARATION AND USE THEREOF |
US9539290B2 (en) | 2012-12-24 | 2017-01-10 | Anticancer Inc. | Individualized bacterial treatment of pancreatic cancer |
WO2014198002A1 (en) | 2013-06-14 | 2014-12-18 | Ottawa Hospital Research Institute | A bacterium producing an interferon binding protein and uses thereof |
US20160287623A1 (en) | 2013-11-19 | 2016-10-06 | The University Of Chicago | Use of sting agonist as cancer treatment |
WO2015078840A1 (en) | 2013-11-26 | 2015-06-04 | Boehringer Ingelheim International Gmbh | Full and partial protein secretion and cell surface display using type iii secretion system |
CN107002090B (zh) * | 2014-05-01 | 2021-09-10 | 阿苏萨医药科学有限公司 | 异源多肽表达盒 |
JP7080053B2 (ja) | 2014-08-29 | 2022-06-03 | ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム | 腫瘍の治療のための、キヌレニンを枯渇させる酵素の投与 |
SG11201704543XA (en) | 2014-12-05 | 2017-07-28 | Synlogic Inc | Bacteria engineered to treat diseases associated with hyperammonemia |
US9688967B2 (en) | 2014-12-05 | 2017-06-27 | Synlogic, Inc. | Bacteria engineered to treat diseases associated with hyperammonemia |
US10617729B2 (en) | 2014-12-24 | 2020-04-14 | The Uab Research Foundation | Multitargeting onocolytic adenovirus, methods of use, and methods of making |
US20160220652A1 (en) * | 2015-02-03 | 2016-08-04 | Advaxis, Inc. | Methods of using recombinant listeria vaccine strains in disease immunotherapy |
CA3013713A1 (en) * | 2015-02-11 | 2016-08-18 | The Johns Hopkins University | Bacteria over-expressing c-di-amp and therapeutic methods |
EP3294757B1 (en) * | 2015-05-13 | 2023-12-27 | Synlogic Operating Company, Inc. | Bacteria engineered to treat a disease or disorder |
WO2016191283A2 (en) | 2015-05-22 | 2016-12-01 | University Of Houston System | Enzymatic immunomodulation of solid tumors and user thereof |
WO2016210373A2 (en) * | 2015-06-24 | 2016-12-29 | Synlogic, Inc. | Recombinant bacteria engineered for biosafety, pharmaceutical compositions, and methods of use thereof |
WO2017123675A1 (en) | 2016-01-11 | 2017-07-20 | Synlogic, Inc. | Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells |
EP3565566A1 (en) | 2017-01-06 | 2019-11-13 | Synlogic Operating Company, Inc. | Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells |
KR20200064980A (ko) | 2017-07-12 | 2020-06-08 | 신로직 오퍼레이팅 컴퍼니, 인코포레이티드 | 종양 세포에서 면역 조절제 및 항-암 치료제를 생산하도록 프로그램된 미생물 |
BR112021000315A2 (pt) | 2018-07-11 | 2021-08-03 | Actym Therapeutics, Inc. | cepas bacterianas imunoestimulantes modificadas geneticamente e seus usos |
EP3844276A2 (en) | 2018-08-28 | 2021-07-07 | Actym Therapeutics, Inc. | Engineered immunostimulatory bacterial strains and uses thereof |
US20220023358A1 (en) | 2018-11-08 | 2022-01-27 | Synlogic Operating Company, Inc. | Combination therapies of microorganisms and immune modulators for use in treating cancer |
-
2018
- 2018-01-05 EP EP18701238.0A patent/EP3565566A1/en not_active Withdrawn
- 2018-01-05 CA CA3049579A patent/CA3049579A1/en active Pending
- 2018-01-05 WO PCT/US2018/012698 patent/WO2018129404A1/en unknown
- 2018-01-05 SG SG11201906161VA patent/SG11201906161VA/en unknown
- 2018-01-05 CN CN201880016704.4A patent/CN110913875A/zh active Pending
- 2018-01-05 BR BR112019013863-3A patent/BR112019013863A2/pt not_active IP Right Cessation
- 2018-01-05 JP JP2019536929A patent/JP2020505016A/ja active Pending
- 2018-01-05 MX MX2019008196A patent/MX2019008196A/es unknown
- 2018-01-05 AU AU2018205276A patent/AU2018205276A1/en not_active Abandoned
- 2018-01-05 US US16/474,383 patent/US11471494B2/en active Active
-
2019
- 2019-07-03 IL IL267830A patent/IL267830A/en unknown
-
2022
- 2022-08-02 US US17/879,559 patent/US20230226122A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20190336544A1 (en) | 2019-11-07 |
JP2020505016A (ja) | 2020-02-20 |
CA3049579A1 (en) | 2018-07-12 |
AU2018205276A1 (en) | 2019-07-18 |
BR112019013863A2 (pt) | 2020-03-03 |
WO2018129404A8 (en) | 2019-06-13 |
US11471494B2 (en) | 2022-10-18 |
US20230226122A1 (en) | 2023-07-20 |
IL267830A (en) | 2019-09-26 |
CN110913875A (zh) | 2020-03-24 |
WO2018129404A1 (en) | 2018-07-12 |
SG11201906161VA (en) | 2019-08-27 |
EP3565566A1 (en) | 2019-11-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019008196A (es) | Microorganismos programados para producir moduladores inmunes y productos terapéuticos anti-cáncer en células tumorales. | |
WO2017123675A8 (en) | Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells | |
IL270892A (en) | Microorganisms are programmed to produce immune modulators and anti-cancer treatments in squamous cells | |
BR112017024384A2 (pt) | bactérias modificadas para reduzir hiperfenilalaninemia | |
PH12020552039A1 (en) | Binding molecules against bcma and uses thereof | |
GB2557123A (en) | Modified cells and methods of therapy | |
MX2021006581A (es) | Bacterias modificadas para tratar enfermedades asociadas con hiperamonemia. | |
SA518400424B1 (ar) | جزيئات الجسم المضاد لعلاج السرطان | |
PH12017500022A1 (en) | Carrier-antibody compositions and methods of making and using the same | |
GB2573406A (en) | Tumor infiltrating lymphocytes and methods of therapy | |
MX2016016881A (es) | Anticuerpos que se unen a axl. | |
PH12019502602A1 (en) | Polypeptides antagonizing wnt signaling in tumor cells | |
WO2016183532A8 (en) | Bacteria engineered to treat a disease or disorder | |
MX2022012013A (es) | Composiciones y metodos para transduccion de tumores. | |
MX2018001755A (es) | Vacuna contra viruela para tratamiento del cancer. | |
MX2019010039A (es) | Composiciones y métodos para transducción de tumores. | |
TR201901077T4 (tr) | Kanser Veya Enfeksiyon Tedavisine Yönelik Birleşik Preparasyonlar | |
MX2017012867A (es) | Composiciones terapeuticas y metodos de uso para tratar el cancer. | |
WO2018102589A3 (en) | Anti-hrs antibodies and combination therapies for treating cancers | |
PH12021551036A1 (en) | Anti-liv1 immune cell cancer therapy | |
MX2018005825A (es) | Celulas inmunes modificadas y usos de las mismas. | |
NZ731398A (en) | Noscapinoid-producing microbes and methods of making and using the same | |
MX2018015172A (es) | Metodos para tratar cancer pancreatico. | |
PH12021551047A1 (en) | Anti-ptk7 immune cell cancer therapy | |
MX2022005790A (es) | Elementos reguladores de planta y metodos para usarlos. |